Avatrombopag Use in Patient With Thromboembolic Risks Listed for Combined Coronary Artery Bypass Grafting and Liver Transplant: A Case Report

Bassem Almalki; Hersh Shroff; Haripriya Maddur; Juan Caicedo; Clare Kane

doi:10.1016/j.transproceed.2021.08.011

Avatrombopag Use in Patient With Thromboembolic Risks Listed for Combined Coronary Artery Bypass Grafting and Liver Transplant: A Case Report

Bassem Almalki^*, Hersh Shroff, Haripriya Maddur, Juan Caicedo, Clare Kane

^*Corresponding author for this work

Surgery, Transplant Surgery Division

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Thrombocytopenia commonly occurs in patients with advanced liver disease and can be a contraindication in patients needing combined coronary artery bypass grafting (CABG) and liver transplant (LT). Thrombopoietin receptor agonists, including avatrombopag, are part of a novel drug class and stimulate platelet production. Avatrombopag is indicated in the perioperative setting to avoid platelet transfusions, which carry several disadvantages. Avatrombopag was shown to be safe and effective in patients with chronic liver disease. This study describes the successful use of avatrombopag in a patient with thromboembolic risks in preparation for a combined CABG and LT. Larger clinical trials are necessary to validate our results.

Original language	English (US)
Pages (from-to)	2567-2569
Number of pages	3
Journal	Transplantation proceedings
Volume	53
Issue number	8
DOIs	https://doi.org/10.1016/j.transproceed.2021.08.011
State	Published - Oct 2021

ASJC Scopus subject areas

Transplantation
Surgery

Access to Document

10.1016/j.transproceed.2021.08.011

Cite this

@article{62a5f86e40a244d480ea08d332a44c8d,

title = "Avatrombopag Use in Patient With Thromboembolic Risks Listed for Combined Coronary Artery Bypass Grafting and Liver Transplant: A Case Report",

abstract = "Thrombocytopenia commonly occurs in patients with advanced liver disease and can be a contraindication in patients needing combined coronary artery bypass grafting (CABG) and liver transplant (LT). Thrombopoietin receptor agonists, including avatrombopag, are part of a novel drug class and stimulate platelet production. Avatrombopag is indicated in the perioperative setting to avoid platelet transfusions, which carry several disadvantages. Avatrombopag was shown to be safe and effective in patients with chronic liver disease. This study describes the successful use of avatrombopag in a patient with thromboembolic risks in preparation for a combined CABG and LT. Larger clinical trials are necessary to validate our results.",

author = "Bassem Almalki and Hersh Shroff and Haripriya Maddur and Juan Caicedo and Clare Kane",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",

year = "2021",

month = oct,

doi = "10.1016/j.transproceed.2021.08.011",

language = "English (US)",

volume = "53",

pages = "2567--2569",

journal = "Transplantation proceedings",

issn = "0041-1345",

publisher = "Elsevier USA",

number = "8",

}

TY - JOUR

T1 - Avatrombopag Use in Patient With Thromboembolic Risks Listed for Combined Coronary Artery Bypass Grafting and Liver Transplant

T2 - A Case Report

AU - Almalki, Bassem

AU - Shroff, Hersh

AU - Maddur, Haripriya

AU - Caicedo, Juan

AU - Kane, Clare

PY - 2021/10

Y1 - 2021/10

N2 - Thrombocytopenia commonly occurs in patients with advanced liver disease and can be a contraindication in patients needing combined coronary artery bypass grafting (CABG) and liver transplant (LT). Thrombopoietin receptor agonists, including avatrombopag, are part of a novel drug class and stimulate platelet production. Avatrombopag is indicated in the perioperative setting to avoid platelet transfusions, which carry several disadvantages. Avatrombopag was shown to be safe and effective in patients with chronic liver disease. This study describes the successful use of avatrombopag in a patient with thromboembolic risks in preparation for a combined CABG and LT. Larger clinical trials are necessary to validate our results.

AB - Thrombocytopenia commonly occurs in patients with advanced liver disease and can be a contraindication in patients needing combined coronary artery bypass grafting (CABG) and liver transplant (LT). Thrombopoietin receptor agonists, including avatrombopag, are part of a novel drug class and stimulate platelet production. Avatrombopag is indicated in the perioperative setting to avoid platelet transfusions, which carry several disadvantages. Avatrombopag was shown to be safe and effective in patients with chronic liver disease. This study describes the successful use of avatrombopag in a patient with thromboembolic risks in preparation for a combined CABG and LT. Larger clinical trials are necessary to validate our results.

UR - http://www.scopus.com/inward/record.url?scp=85114005823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85114005823&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2021.08.011

DO - 10.1016/j.transproceed.2021.08.011

M3 - Article

C2 - 34474911

AN - SCOPUS:85114005823

SN - 0041-1345

VL - 53

SP - 2567

EP - 2569

JO - Transplantation proceedings

JF - Transplantation proceedings

IS - 8

ER -

Avatrombopag Use in Patient With Thromboembolic Risks Listed for Combined Coronary Artery Bypass Grafting and Liver Transplant: A Case Report

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this